Guo Jun, Shi Lei, Li Min, Xu Jin, Yan Shushan, Zhang Chuang, Sun Guan
Department of Neurosurgery, Fourth Affiliated Hospital of Nantong University, First Hospital of Yancheng, Yancheng, 224001, People's Republic of China.
Tumour Biol. 2014 Jan;35(1):573-9. doi: 10.1007/s13277-013-1080-9. Epub 2013 Aug 27.
Potential single-nucleotide polymorphisms (SNPs) of interleukin-4 receptor alpha (IL-4Rα) rs1801275 and rs1805015 have been implicated in glioma risk; however, the findings of previous published case-control studies are conflicting and inconclusive. We performed the updated meta-analysis with the aim to provide a more precise estimate for the role of interleukin-4Rα SNPs in glioma risk. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the strength of the gene association. Overall, the pooled analysis showed that the IL-4Rα rs1801275 polymorphism was associated with a decreased risk of glioma in the comparison of G vs. A (OR = 0.87, 95% CI = 0.76-0.99, P OR = 0.041). Subgroup analysis by ethnicity revealed that the IL-4Rα rs1801275 variant G and GG + AG exerted a decreased risk effect on the development of glioma among Asians, but not Caucasians (G vs. A, OR = 0.81, 95% CI = 0.69-0.95, P OR = 0.011; GG + AG vs. AA, OR = 0.80, 95% CI = 0.66-0.96, P OR = 0.018). However, the IL-4Rα rs1805015 polymorphism did not modify the risk of glioma. Sensitivity analysis confirmed the reliability for all of the results. Our meta-analysis suggests that the polymorphism of IL-4Rα rs1801275 but not IL-4Rα rs1805015 plays a protective role in the glioma pathogenesis, particularly among Asians.
白细胞介素-4受体α（IL-4Rα）的潜在单核苷酸多态性（SNP）rs1801275和rs1805015与胶质瘤风险有关；然而，先前发表的病例对照研究结果相互矛盾且尚无定论。我们进行了更新的荟萃分析，旨在更精确地评估白细胞介素-4Rα SNP在胶质瘤风险中的作用。采用合并比值比（OR）及95%置信区间（CI）来评估基因关联强度。总体而言，合并分析显示，在G与A的比较中，IL-4Rα rs1801275多态性与胶质瘤风险降低相关（OR = 0.87，95% CI = 0.76 - 0.99，P OR = 0.041）。按种族进行的亚组分析显示，IL-4Rα rs1801275变异型G以及GG + AG在亚洲人中对胶质瘤的发生具有降低风险的作用，但在白种人中并非如此（G与A比较，OR = 0.81，95% CI = 0.69 - 0.95，P OR = 0.011；GG + AG与AA比较，OR = 0.80，95% CI = 0.66 - 0.96，P OR = 0.018）。然而，IL-4Rα rs1805015多态性并未改变胶质瘤风险。敏感性分析证实了所有结果的可靠性。我们的荟萃分析表明，IL-4Rα rs1801275的多态性而非IL-4Rα rs1805015在胶质瘤发病机制中起保护作用，尤其是在亚洲人中。
